OncoCell MDx Announces Mark McDonough as New President & Chief Executive Officer

ROYAL OAK, Mich.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/OncoCellMDx?src=hash” target=”_blank”gt;#OncoCellMDxlt;/agt;–OncoCell MDx, a company developing novel noninvasive diagnostic and
prognostic tests by harnessing the power of the immune system, today
announced the appointment of Mark McDonough as its president, chief
executive officer (CEO) and member of the Board of Directors. McDonough
succeeds company co-founder, investor and Chairman/CEO Harry Stylli,
Ph.D. Stylli continues as the executive chairman of the company.

“Since OncoCell’s founding, we have built an outstanding research and
development capability and advanced a proprietary platform that exploits
the power of the immune system and machine learning to non-invasively
identify robust disease signatures for many pathologies. Although the
platform has the capability to target any analyte, we chose to exploit
gene expression. To date we have analyzed about 2,000 patient samples to
identify a unique immunogenomic signature that can discriminate subjects
with indolent and aggressive prostate cancer from normal controls. With
the presentation of promising results from our recent study
at the American Association for Cancer Research Annual Meeting, we
demonstrated the potential of our technology to aid in early detection
and progression of disease pathology,” said Stylli.

“Mark has an outstanding track record in generating significant value at
both large and small companies in the molecular diagnostics field and
especially for companies like ours that are approaching
commercialization,” he added. “I’m excited that he will lead OncoCell
MDx in our mission to bring novel technologies to market that help
physicians better manage patients with prostate cancer and other

McDonough most recently served as the chief business officer at
Phosphorus, a genomic health company, where he helped increase the
company’s revenue by more than tenfold in less than a year. Prior to
joining Phosphorus, McDonough served as chief executive officer and
president of CombiMatrix, a publicly held molecular diagnostics company
performing DNA-based testing services for reproductive health and
developmental disorders, through its acquisition by Invitae Corp. He
also held executive and management positions with US LABS (acquired by
LabCorp) and Ventana Medical Systems (acquired by Roche) as well as
Pathwork Diagnostics.

“OncoCell’s platform facilitates not just detection, but also grading
and aggressiveness of disease, leading to more timely and better
directed medical decision making. I’m inspired by the company’s
potential to improve the quality, effectiveness and efficiency of
patient care, and I’m humbled to lead what is already a very strong team
into our next stage of clinical and corporate development,” McDonough
said. “I would like to thank the Board and Harry Stylli for the
opportunity to build on the company’s successes and momentum as we
continue to move OncoCell MDx forward.”

McDonough is currently an advisor for Phosphorus and Natal Health. He is
a former navigator in the U.S. Navy and holds a B.S. in Finance from
Miami University.

About OncoCell MDx

OncoCell MDx is a privately held company developing and commercializing
novel diagnostic tests utilizing proprietary technologies created at
Harvard Medical School. The company’s noninvasive blood-based
immunogenomic assays are designed to aid physicians to better understand
underlying disease pathology in prostate cancer and other oncology and
non-oncology indications.


Press Contact:
Virginia Amann for OncoCell MDx
[email protected]

error: Content is protected !!